Our R&D Capability

Since its establishment, PeptiDream has continuously expanded its R&D functions. Initially focused on obtaining hit compounds using PDPS, we established in-house capabilities in protein preparation, peptide synthesis/purifications/QC, medicinal chemistry, in silico modelling and informatics, co-crystallization and conformational analysis of proteins and compounds, and pharmacokinetics, which fulfill most roles leading up to preclinical studies. This expansion enables us to work on a large number of projects at the same time and to conduct R&D activities at high standards required by all collaboration partners.

In addition, we established an automated platform for PDPS which dramatically improved the efficiency of the work process compared to manual procedures. As a result, various hit peptides can be found with higher certainty, as the automated platform enables us to easily perform the PDPS process in a high-throughput format under a wide variety of conditions (e.g., target protein type, temperature, amino acids) with higher accuracy.

Since April 2022, PDRadiopharma which develops, manufactures and markets radiopharmaceuticals, became a 100% subsidiary of PeptiDream. We are also focusing on the creation of new peptide-radionuclide conjugates (RI-PDC) that combine the technology and know-how of PeptiDream with the expertise of PDRadiopharma. In this RI-PDC field, we are currently conducting multiple drug discovery and development collaborations though partnershipsand strategic alliances. We believe that we will be able to deliver novel RI-PDCs globally through our partners outside of Japan and domestic development by PDRadiopharma.